This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Navidea Biopharmaceuticals Participates In Symposium Focused On Sentinel Lymph Node Biopsy At The International Symposium On Metastasis In Head And Neck Cancer

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced that it recently participated in a focused panel session at the 6th International Symposium on Metastasis in Head and Neck Cancer held in Marburg, Germany. Lymphoseek ® (technetium Tc 99m tilmanocept) Injection and initial clinical experience data from one site participating in the Lymphoseek head and neck cancer clinical trial, NEO3-06, were discussed during a satellite symposium focused on Sentinel Lymph Node (SLN) biopsy in Head and Neck Cancer. In this session, presentations were made by a panel of head and neck specialists which included Lymphoseek-related presentations from Navidea’s Chief Medical Officer, Cornelia Reininger, MD, PhD and Francisco J. Civantos, MD, FACS, Head & Neck / Skull Base Surgery, University of Miami. Lymphoseek is a receptor-targeted, small-molecule, investigational radiopharmaceutical used in lymphatic mapping procedures.

“It was enlightening for the delegates to understand more about sentinel node localization and the specific function of Lymphoseek. Following significant panel and expert discussion, it was agreed that sentinel node localization has a vital role in head and neck cancers and should be applied in routine clinical care,” Prof. John Buscombe, Head of the Department of Nuclear Medicine at Cambridge University Hospitals, Cambridge, UK commented. “However, current radioactive colloids often display variable performance and the limitation of being of human or animal origin. These data appear to indicate that lymphatic mapping procedures can be improved using an agent such as Lymphoseek which shows more accurate localization of the sentinel node or nodes and will lead to less aggressive surgery, more accurate staging of disease and fewer side effects.”

Professsor Buscombe acted as moderator for the session and described the history and technique of sentinel node localization and demonstrated that the technique was safe for the surgeons, their assistants and the pathologists. Dr. Reininger provided a summary of Lymphoseek’s performance advantages in lymphatic mapping of solid tumor cancers. Data demonstrated Lymphoseek’s rapid clearance from the injection site but stability in the sentinel node for up to 24 hours and reinforced its ability to accurately identify and map SLNs that can facilitate accurate staging and may potentially decrease some patients’ extent of surgery, thus reducing possible serious morbidity. Professor Civantos spoke of the University of Miami’s initial clinical experience with Lymphoseek. Results to date have demonstrated its utility, diagnostic predictive value and safety in patients, both preoperatively in lymphoscintigraphy and for intraoperative localization.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.02 1.50%
FB $117.97 -0.51%
GOOG $694.98 -0.46%
TSLA $236.00 -2.40%
YHOO $36.09 -1.20%


Chart of I:DJI
DOW 17,737.89 -153.27 -0.86%
S&P 500 2,061.91 -19.52 -0.94%
NASDAQ 4,767.95 -49.6440 -1.03%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs